Psoriatic Disease

Patients with rheumatoid arthritis who receive TNF inhibitors are more likely to develop psoriasis vs. those treated with methotrexate, according to an analysis of more than 880,000 post-marketing reports published in Scientific Reports.

Age, disease duration and sex are factors that may predict how likely a patient with psoriatic arthritis may be to enter remission following therapy with a TNF inhibitor, according to data published in Rheumatology.

Among patients with psoriasis, arthralgia should be considered a risk factor predicting progression to psoriatic arthritis, according to new EULAR points to consider for suspicious features in early PsA development.

Patients with axial spondyloarthritis and psoriatic arthritis routinely “bounce” from one provider to the next for years before finally receiving the correct diagnosis in a rheumatology clinic, according to experts.

The adalimumab biosimilar Hadlima achieved its pharmacokinetic similarity endpoints in a phase 4 interchangeability study, according to a press release from the manufacturer.

AUSTIN, Texas — Communication and awareness of the myriad disease domains are essential to preventing a misdiagnosis of psoriatic arthritis, according to a presenter at the 2023 Rheumatology Nurses Society annual conference.

Factors associated with multiple biologic failure in patients with psoriasis may indicate who would benefit from frequent follow-up, according to a study.

As August marks the beginning of Psoriasis Action Month, Healio Dermatology has compiled a list of the top psoriasis stories from the past year that bring awareness to the plight of patients with psoriasis and the work of clinicians.

Brepocitinib, in doses of either 30 mg or 60 mg, is superior to placebo in reducing signs and symptoms of psoriatic arthritis and is “generally well tolerated” through 52 weeks, according to data published in Arthritis & Rheumatology.

Cyltezo, the first interchangeable Humira biosimilar, officially entered the U.S. market on July 1, opening a floodgate that will see the release this month of half a dozen biosimilars for what has been the top selling drug in the country.